2-(2-氯-5-硝基苯基)乙酸 | 37777-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-氯-5-硝基苯基)乙酸
• 英文名称: 2-(2-chloro-5-nitrophenyl)acetic acid
• 英文别名: (2-chloro-5-nitrophenyl)acetic acid；(2-chloro-5-nitro-phenyl)-acetic acid；2-chloro-5-nitro-benzeneacetic acid；(2-chloro-5-nitro)phenylacetic acid；2-chloro-5-nitro-phenylacetic acid；(2-Chlor-5-nitrophenyl)-essigsaeure
• CAS: 37777-70-1
• 化学式: C₈H₆ClNO₄
• 分子量: 215.593
• InChiKey: KNCGDIHMXCSJDC-UHFFFAOYSA-N

物化性质

• 熔点：
  174-175 °C(Solv: acetic acid (64-19-7); water (7732-18-5))
• 沸点：
  398.3±27.0 °C(Predicted)
• 密度：
  1.532±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-(2-氯-5-硝基苯基)乙酸 在 sodium tungstate (VI) dihydrate 盐酸 、 双氧水 、 potassium carbonate 、 N,N'-羰基二咪唑 作用下， 以 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 22.25h， 生成 6-(2-chloro-5-nitrophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one
  参考文献：
  名称：

  RAF INHIBITORS

  摘要：

  本发明提供了吡啶并[2,3-d]嘧啶-7-酮的衍生物。这些化合物是Raf等激酶的抑制剂，包括表现出抗增殖活性的化合物，包括对肿瘤细胞的抗活性，并且在治疗癌症等疾病方面是有用的。

  公开号：

  US20110257207A1
• 作为产物：
  描述：

  2-氯-5-硝基甲苯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 生成 2-(2-氯-5-硝基苯基)乙酸
  参考文献：
  名称：

  Lisitsyn,V.N.; Lugovskaya,E.K., Journal of Organic Chemistry USSR (English Translation), 1974, vol. 10, p. 92 - 95

  摘要：

  DOI：

文献信息

• Diaryl sulphide derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US04771062A1

  公开（公告）日：1988-09-13

  A diaryl sulphide derivative of the formula ##STR1## in which R.sup.1 represents a thiazolamino radical of the formulae ##STR2## wherein R.sup.5 represents hydrogen, alkyl, aralkyl or acyl, R.sup.6 and R.sup.6 ' are identical or different and represent hydrogen, alkyl, aralkyl or aryl, R.sup.7 represents alkyl, cycloalkyl, aralkyl, acyl or aryl and n represents the number 1 or 2, R.sup.2 and R.sup.3 are identical or different and represent hydrogen, alkyl, alkenyl, cycloalkyl, alkoxy, alkylthio, halogenoalkyl, halogenoalkoxy, halogenoalkylthio, aryl, aralkyl, aryloxy, aralkoxy, aralkylthio, acyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, nitro, cyano or halogen, or represent a group of the formula ##STR3## wherein R.sup.8 and R.sup.9 are identical or different and represent hydrogen, alkyl, aryl, aralkyl, acyl, trifluoroacetyl, alkylsulphonyl, arylsulphonyl, trifluoromethylphenylsulphonyl or tolylsulphonyl and R.sup.4 has one of the abovementioned meanings or R.sup.1, or represents hydrogen, alkyl, alkenyl, cycloalkyl, alkoxy, alkylthio, halogenoalkyl, halogenoalkoxy, halogenoalkylthio, aryl, aralkyl, aryloxy, aralkoxy, aralkylthio, acyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, nitro, cyano or halogen, or represents a group of the formula ##STR4## wherein R.sup.8 and R.sup.9 have the abovementioned meanings, and salts thereof. Such diaryl sulphide derivatives being useful as active compounds in the treatment and prevention of diseases of the respiratory tract and cardiovascular diseases.

  公式为##STR1##的二芳基硫醚衍生物，其中R.sup.1代表公式##STR2##中的噻唑氨基基团，其中R.sup.5代表氢、烷基、芳基烷基或酰基，R.sup.6和R.sup.6'相同或不同，代表氢、烷基、芳基烷基或芳基，R.sup.7代表烷基、环烷基、芳基烷基、酰基或芳基，n代表数字1或2，R.sup.2和R.sup.3相同或不同，代表氢、烷基、烯基、环烷基、烷氧基、烷基硫氧基、卤代烷基、卤代烷氧基、卤代烷基硫氧基、芳基、芳基烷基、芳基氧基、芳基烷氧基、芳基烷基硫氧基、酰基、羧基、烷氧羰基、羧基烷基、烷氧羰基烷基、硝基、氰基或卤素，或代表公式##STR3##中的一个基团，其中R.sup.8和R.sup.9相同或不同，代表氢、烷基、芳基、芳基烷基、酰基、三氟乙酰基、烷基磺酰基、芳基磺酰基、三氟甲基苯磺酰基或甲苯磺酰基，R.sup.4具有上述含义之一或R.sup.1，或代表氢、烷基、烯基、环烷基、烷氧基、烷基硫氧基、卤代烷基、卤代烷氧基、卤代烷基硫氧基、芳基、芳基烷基、芳基氧基、芳基烷氧基、芳基烷基硫氧基、酰基、羧基、烷氧羰基、羧基烷基、烷氧羰基烷基、硝基、氰基或卤素，或代表公式##STR4##中的一个基团，其中R.sup.8和R.sup.9具有上述含义，及其盐。这种二芳基硫醚衍生物在治疗和预防呼吸道疾病和心血管疾病中作为活性化合物是有用的。
• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• Noncataleptic neuroleptic agents: 2-Halogeno-8-isopropyl-10-piperazino-10,11-dihydrodibenzo[b,f,]thiepins
  作者：Zdeněk Polívka、Jiří Jílek、Jiří Holubek、Emil Svátek、Antonín Dlabač、Martin Valchář、Miroslav Protiva

  DOI：10.1135/cccc19840086

  日期：——

  Reactions of 5-fluoro, 5-chloro- and 5-bromo-2-iodobenzoic acid with 4-isopropylthiophenol in solutions of potassium hydroxide in the presence of copper gave the acids VIIabc which were transformed via the intermediates VIIIabc-Xabc to 2-[5-halogeno-2-(4-isopropylphenylthio)-phenyl]acetic acids XIabc. Their cyclization with polyphosphoric acid resulted in 2-halogeno-8-isopropyldibenzo[b,f]thiepin-10(11H)-ones XIIabc.The 2-iodo ketone XIId was obtained from 2-(2-chloro-5-nitrophenyl)acetic acid by treatment with 4-isopropylthiophenol, by the following reduction of the resulting nitro acid XIe with hydrazine to the amino acid XIf, by its cyclization to the amino ketone XIIf and finally by its diazotization and reaction with potassium iodide. The ketones XIIa-d were reduced to the alcohols XIIIa-d giving by treatment with hydrogen chloride the chloro compounds XIVa-d. Substitution reactions with 1-methylpiperazine and 1-(2-hydroxyethyl)piperazine afforded the title compounds Vabc and VIa-d. Only the fluoro derivatives Va and VIa showed a clear cataleptic activity in rats. The other compounds are very little active in this line and the iodo derivative VId was found to be completely inactive in a high oral dose, but it revealed an intensive antidopaminergic action in biochemical tests. By its pharmacological profile it resembles the known noncataleptic neuroleptic agent clozapine.

  5-氟、5-氯和5-溴-2-碘苯甲酸与4-异丙基硫酚在氢氧化钾溶液中，在铜的存在下反应，生成了酸VIIabc，这些酸通过中间体VIIIabc-Xabc转化为2-[5-卤代-2-(4-异丙基苯硫基)苯基]乙酸XIabc。它们与多磷酸的环化反应产生了2-卤代-8-异丙基二苯并[b,f]噻吩-10(11H)-酮XIIabc。2-碘代酮XIId是通过2-(2-氯-5-硝基苯基)乙酸与4-异丙基硫酚反应，随后将生成的硝基酸XIe用肼还原为氨基酸XIf，再通过其环化成氨基酮XIIf，最后通过重氮化和与碘化钾反应得到的。酮XIIa-d被还原为醇XIIIa-d，通过与氯化氢处理得到氯化物XIVa-d。与1-甲基哌嗪和1-(2-羟乙基)哌嗪的取代反应得到了标题化合物Vabc和VIa-d。只有氟代衍生物Va和VIa在大鼠中显示出明显的僵住活性。其他化合物在这方面活性很低，碘代衍生物VId在高口服剂量下被发现完全无活性，但它显示出强烈的抗多巴胺能作用在生化测试中。根据其药理学特征，它类似于已知的非僵住性神经安定剂氯氮平。
• Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
  申请人：Flynn Daniel L.

  公开号：US08461179B1

  公开（公告）日：2013-06-11

  The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

  这项发明涉及二氢萘啶和相关化合物；包括有效量二氢萘啶或相关化合物的组合物；以及治疗或预防增生性疾病的方法，包括给予有效量二氢萘啶或相关化合物。
• [EN] DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DIHYDRONAPHTYRIDINES ET COMPOSÉS APPARENTÉS UTILES COMME INHIBITEURS DE KINASES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：FLYNN DANIEL L

  公开号：WO2013184119A1

  公开（公告）日：2013-12-12

  The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

  该发明涉及二氢萘啶并相关化合物；包含有效量二氢萘啶或相关化合物的组合物；以及治疗或预防增生性疾病的方法，包括给予有效量二氢萘啶或相关化合物。本发明揭示了抑制cKIT激酶的化合物在广泛范围内对c-KIT突变具有意想不到的功效，包括抑制原发性突变（KIT外显子9或11）和次级KIT突变（外显子13、14、17和18）的复杂发生，这些可能出现在个体、难治性GIST患者身上。同样令人意想不到的是本发明的化合物对抑制目前没有有效治疗的问题性外显子17 D816V c-KIT突变的功效。